Changes in blood pressure rhythm after new quadruple anti-heart failure treatment and its impact on heart failure prognosis

We assessed the effects of a new quadruple anti-heart failure treatment on the blood pressure rhythm of patients with acute heart failure and its relationship with heart failure prognosis. A total of 135 patients with heart failure were treated with the new quadruple anti-heart failure treatment. Dynamic blood pressure was monitored before and after treatment for 12 to 16 weeks, and changes in the blood pressure rhythm were analyzed. The Kaplan-Meier method was used to calculate the 1-year incidence of major adverse cardiovascular events (MACE). Before and after 12 to 16 weeks of the new quadruple anti-heart failure treatment, the respective mean blood pressure drop rates were 0.44% ± 0.086 and 4.42% ± 0.068 (t = -6.149, P < .001); the systolic blood pressure (SBP) drop rates were 0.54% ± 0.089 and 5.59% ± 0.069 (t = -7.534, P < .001); and the diastolic blood pressure (DBP) drop rates were 0.25% ± 0.104 and 3.37% ± 0.08 (t = -3.943, P < .001); while the mean blood pressure dipper type ratios were 13.3% and 25.9% (χ² = 29.077, P < .001); the systolic dipper type ratios were 13.3% and 28.1% (χ² = 7.714, P = .005); and the diastolic dipper type ratios were 12.6% and 23.0% (χ² = 14.139, P < .001). The 1-year MACE incidence rate in the posttreatment dipper-type blood pressure group was lower than that in the non-dipper-type group (P < .05), and the 1-year MACE incidence rate in patients with improvement in blood pressure rhythm after treatment was lower than that in the non-improvement group (P < .05). The blood pressure rhythms before and after treatment were finally divided into 4 subgroups; 1-year MACE incidence in the mean blood pressure rhythm (P = .037), SBP rhythm (P = .008), and DBP rhythm (P = .005) was the lowest in the dipper-type dipper type group. The new quadruple anti-heart failure treatment regimen can improve the blood pressure rhythm in patients with acute heart failure, and this improvement was associated with a decreased MACE incidence in these patients within 1 year.